Published in Rambam Maimonides Med J on April 30, 2012
Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2007) 22.81
Cardiac excitation-contraction coupling. Nature (2002) 18.48
Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation (1990) 9.74
Beta-arrestins and cell signaling. Annu Rev Physiol (2007) 8.65
Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol (2000) 7.17
Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med (1982) 6.79
Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov (2010) 5.76
Seven-transmembrane-spanning receptors and heart function. Nature (2002) 5.38
Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev (2007) 4.69
PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med (2004) 4.50
Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science (2011) 4.36
A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A (2007) 3.82
Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science (2002) 3.46
Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest (2007) 3.15
Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A (1999) 3.13
Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell (2005) 3.01
Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther (2008) 2.93
Calcium cycling in congestive heart failure. J Mol Cell Cardiol (2002) 2.46
Leaky Ca2+ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. J Clin Invest (2008) 2.45
Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation (2010) 2.37
Altered cardiac myocyte Ca regulation in heart failure. Physiology (Bethesda) (2006) 2.29
Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet (2011) 2.25
Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res (1985) 2.23
Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation (2005) 2.23
Molecular regulation of cardiac hypertrophy. Int J Biochem Cell Biol (2008) 1.95
Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation (2006) 1.73
Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation (2006) 1.64
Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol (2008) 1.60
Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc Natl Acad Sci U S A (2000) 1.57
Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail (2010) 1.57
Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med (2011) 1.54
Cardiac inotropes: current agents and future directions. Eur Heart J (2011) 1.53
Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev (2011) 1.49
Impaired cardiac contractility response to hemodynamic stress in S100A1-deficient mice. Mol Cell Biol (2002) 1.43
Targeting myocardial substrate metabolism in heart failure: potential for new therapies. Eur J Heart Fail (2012) 1.36
AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J (2012) 1.35
Regulation of cardiac and smooth muscle Ca(2+) channels (Ca(V)1.2a,b) by protein kinases. Am J Physiol Cell Physiol (2001) 1.34
GRK2 as a novel gene therapy target in heart failure. J Mol Cell Cardiol (2010) 1.31
New targets to treat the structural remodeling of the myocardium. J Am Coll Cardiol (2011) 1.17
Plasma membrane Ca2+-ATPase isoform 4 antagonizes cardiac hypertrophy in association with calcineurin inhibition in rodents. J Clin Invest (2009) 1.17
S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy. J Mol Cell Cardiol (2009) 1.13
Β-arrestin: a signaling molecule and potential therapeutic target for heart failure. J Mol Cell Cardiol (2010) 1.11
Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction. Am J Physiol Heart Circ Physiol (2010) 1.03
Modulation of sarcoplasmic reticulum function by Na+/K+ pump inhibitors with different toxicity: digoxin and PST2744 [(E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride]. J Pharmacol Exp Ther (2004) 0.83
Local signals with global impacts and clinical implications: lessons from the plasma membrane calcium pump (PMCA4). Biochim Biophys Acta (2010) 0.82